Scientific advisory board
Martin Glennie, Professor in immunochemistry at the University of Southampton. World-leading scientist in antibody biology. Dr Glennie’s group has pioneered characterization of molecular mechanisms underlying therapeutic activity of clinically validated antibodies, forming the basis for development of new generations of antibody drugs.
Falk Nimmerjahn, Professor in experimental immunology and immune therapy at the Friedrich-Alexander University Erlangen-Nürnberg. Leading scientist within Fc:FcgR biology and its impact on the therapeutic efficacy and tolerability of antibodies.
Rienk Offringa, Professor at the German Cancer Research Center. Head of a European consortium engaged in immune stimulating anti-cancer antibodies. Formerly Principal Scientist at Genentech.
Tony Tolcher, former Director of Clinical Research at South Texas Accelerated Research Therapeutics (START) and now active in the company NEXT Oncology. Dr. Tolcher specialises in early phase clinical testing of exploratory anti-cancer drugs.
Alexander Rudensky, Chair of the Immunology Program at Sloan Kettering Institute. Dr Rudensky is a world-leading scientist within the area of regulatory T-cells, specialized in CD4-T cell regulation and homeostasis, and its role in autoimmunity and cancer.
The main task of the Scientific Advisory Board, chaired by Professor Martin Glennie, University of Southampton, is to provide BioInvent with valuable input in its effort to develop new antibody treatments for various forms of cancer diseases. The Scientific Advisory Board brings together a wealth of knowledge in the areas of antibody and cancer immunobiology relevant to anti-cancer drug development.
BioInvent’s Chief Scientific Officer, Professor Björn Frendéus, has been appointed Secretary of the Scientific Advisory Board.